肺癌
癌症
肺
医学
肺癌的治疗
癌症生物标志物
肿瘤科
内科学
病理
癌症研究
作者
Akbar Khanmohammadi,Ali B.G. Aghaie,Ensieh Vahedi,Ali Qazvini,Mostafa Ghanei,Abbas Afkhami,Ali Hajian,Hasan Bagheri
出处
期刊:Talanta
[Elsevier]
日期:2019-08-10
卷期号:206: 120251-120251
被引量:274
标识
DOI:10.1016/j.talanta.2019.120251
摘要
Cancer is one of the most widespread challenges and important diseases, which has the highest mortality rate. Lung cancer is the most common type of cancer, so that about 25% of all cancer deaths are related to the lung cancer. The lung cancer is classified as two different types with different treatment methodology: the small cell lung carcinoma and nonsmall cell lung carcinoma are two categories of the lung cancer. Since the lung cancer is often in the latent period in its early stages, therefore, early diagnosis of lung cancer has many challenges. Hence, there is a need for sensitive and reliable tools for preclinical diagnosis of lung cancer. Therefore, many detection methods have been employed for early detection of lung cancer. As lung cancer tumors growth in the body, the cancerous cells release numerous DNA, proteins, and metabolites as special biomarkers of the lung cancer. The levels of these biomarkers show the stages of the lung cancer. Therefore, detection of the biomarkers can be used for screening and clinical diagnosis of the lung cancer. There are numerous biomarkers for the lung cancer such as EGFR, CEA, CYFRA 21-1, ENO1, NSE, CA 19-9, CA 125 and VEGF. Nowadays, electrochemical methods are very attractive and useful in the lung cancer detections. So, in this paper, the recent advances and improvements (2010–2018) in the electrochemical detection of the lung cancer biomarkers have been reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI